Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians – Cora Sternberg
Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved in the US as a first-line therapy, has shifted the treatment paradigm, offering a potent alternative to traditional platinum-based therapies. Dr. Sternberg highlights the importance of this…